Centesis Catheters - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The centesis catheters market size is projected to be USD 0.68 billion in 2025, USD 0.72 billion in 2026, and reach USD 1 billion by 2031, growing at a CAGR of 6.70% from 2026 to 2031. This report is segmented by Product Type (Small-Bore, Large-Bore), Procedure (Paracentesis, Thoracentesis), Application (Drug Administration, Fluid & Nutrition Administration, Blood Transfusion, Hemodialysis), End User (Hospitals, Specialty Clinics, Ascs, Cancer Centers, Home Healthcare), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Market Forecasts in Value (USD).

Global Centesis Catheters Market Trends and Insights

Rising Procedure Volumes for Ascites and Pleural Effusion

Healthcare providers increasingly manage ascites and pleural effusion as chronic conditions requiring planned, repeated drainage, creating recurring demand for the centesis catheters market. An analysis of NHANES data from 2017 to 2024 reported a 35.0% age-adjusted prevalence of steatotic liver disease among U.S. adults, representing nearly 72 million people, with metabolic disease-related fibrosis also increasing. Another study projected that metabolic dysfunction-associated steatotic liver disease prevalence among U.S. adults will increase from 33.7% in 2020 to 41.4% by 2050, while MASH-related cirrhosis cases will nearly double. The World Health Organization stated that hepatitis B and C together cause more than 1.1 million deaths annually and can progress to cirrhosis and ascites. The patient base is becoming younger and more clinically complex as obesity and type 2 diabetes increase among individuals with liver disease. These patients may require drainage over extended care periods, increasing catheter demand without a comparable rise in new diagnoses.

Increasing Adoption of Image-Guided Centesis

Ultrasound guidance has become a standard approach for paracentesis and thoracentesis in North American and European hospitals, reducing reliance on landmark-based placement and improving procedural consistency. A 2025 retrospective review of 134 ultrasound-guided pigtail catheter placements, primarily using 8-10 French catheters, reported a technical success rate above 95%. These findings supported image-guided pleural drainage and increased demand for catheters designed for imaging visibility. This shift encourages hospitals to replace basic products with more specialized systems. Echogenic needle tips, radiopaque catheter bodies, and kink-resistant materials are increasingly important product features. Products such as iVASC M·Drain and Galt Medical Centeze demonstrate the integration of these features into drainage systems. As hospitals standardize image-guided care, features once limited to premium products are becoming broader product specifications. Companies that can upgrade products at scale and provide clinical support may gain an advantage over suppliers of basic catheter-only products.

Premium Pricing and Reimbursement Variability

Branded closed-system kits often cost more than bare-catheter alternatives, particularly in Asia-Pacific and South America, where government reimbursement schedules determine procedure payments. In the United States, CMS procedure codes for paracentesis and thoracentesis did not differentiate between single-use closed drainage kits and open catheter-only setups. Providers may therefore struggle to recover premium kit costs through procedure revenue, limiting adoption in cost-sensitive hospitals. European reimbursement systems can create similar barriers. Swiss DRG information classified percutaneous abdominal drainage under CHOP code 54.91 and DRG Z65A, with a base cost weight of 0.783, while DRG E73B included volume-based adjustments for pleural drainage. These structures may favor shorter drainage volumes and discourage long-dwell catheters, despite their comfort benefits and higher daily device costs.

Other drivers and restraints analyzed in the detailed report include:

• Ambulatory Care and Recurrent Home-Based Drainage
• Palliative Drainage and Closed Workflow Standardization
• Procedure Safety, Training, and System Compatibility

Segment Analysis

Large-bore catheters held a 63.45% share of the centesis catheters market in 2025. These products, typically 12 French (Fr) and above, supported inpatient paracentesis procedures requiring rapid removal of large fluid volumes. They remained widely used in hepatology and oncology wards for fluid accumulation associated with diaphragmatic compression and acute dyspnea. Hospital protocols and group purchasing organization contracts supported their continued use, reinforcing their stable market position.

The others category includes specialized pigtail configurations and trocar-based drainage systems for niche interventional radiology procedures, including multiloculated collections and empyema. Side-hole placement and locking-tail designs support the management of complex fluid collections. Small-bore catheters are forecast to grow at a CAGR of 8.12% from 2026 to 2031; a review of 134 ultrasound-guided 8-10 Fr pigtail placements reported a technical success rate above 95% in pleural drainage. ISO 10993 requirements and FDA 21 CFR 880 regulations apply to both product groups, with compliance costs supporting the pricing power of established suppliers.

Paracentesis accounted for 56.77% of procedure-based revenue in 2025. Repeat treatment for cirrhotic and malignant ascites supported demand, as some patients required drainage every 10-14 days. NHANES findings showed that steatotic liver disease affected 35.0% of US adults between 2017 and 2023, supporting continued demand for drainage services. Group purchasing organization contracts also facilitated recurring purchases of paracentesis kits, while the others category included arthrocentesis and pericardiocentesis procedures requiring specialized designs.

Thoracentesis is forecast to grow at a CAGR of 9.80% from 2026 to 2031, driven by the transition of pleural drainage toward ambulatory care. AMPLE-1 reported median hospitalization of one day for indwelling pleural catheter patients, compared with four days for patients treated with chest drainage and talc pleurodesis. A 2025 study found ambulatory chest drainage and talc pleurodesis to be feasible and safe for malignant pleural effusion. This model reduces hospitalization costs and supports demand for valve-gated and self-sealing catheter systems for use beyond inpatient wards.

Complete Report Scope:

• By Product Type
  • Small-Bore Centesis Catheters
  • Large-Bore Centesis Catheters
  • Others
• By Procedure
  • Paracentesis
  • Thoracentesis
  • Others
• By Application
  • Drug Administration
  • Fluid & Nutrition Administration
  • Blood Transfusion
  • Hemodialysis
• By End User
  • Hospitals & Health Systems
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Cancer Treatment Centers
  • Home Healthcare
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 42.35% of global revenue in 2025, representing the largest centesis catheters market share. High procedure volumes, established image-guided drainage practices, and a mature group purchasing organization structure supported regional demand. U.S. facilities accounted for most revenue as centesis procedures expanded in outpatient oncology and hepatology care. Nearly 72 million U.S. adults had steatotic liver disease during 2017-2023, while fibrosis increased alongside metabolic disease, supporting repeated fluid-drainage procedures through 2031. Canada and Mexico contributed smaller but growing demand through image-guided and home-drainage pathways.

Europe was the second-largest regional market, led by Germany, France, the United Kingdom, and Italy. The United Kingdom had structured indwelling pleural catheter programs supported by community nursing. A February 2025 study reported that patient resources and educational videos for indwelling pleural catheter care reduced unplanned healthcare encounters and improved caregiver competency scores. ewimed collected indwelling pleural catheter implantation information from German centers for 15 years in its 2025 report, based on 2024 data. Italy and Spain expanded palliative centesis protocols in cancer centers, although DRG structures could restrain the uptake of premium closed systems.

Asia-Pacific is forecast to grow at a CAGR of 10.88% through 2031, making it the fastest-growing region in the centesis catheters market. China and India offer the largest incremental volume opportunities as hospital capacity and chronic disease management develop. Japan and South Korea adopted higher-specification catheter technologies, supported by advanced critical-care facilities and aging populations, while Blue Neem Medical Devices and Polymedicure Ltd. increased product-quality competition in India and China. Middle East and Africa demand was supported by tertiary hospital investment in Gulf Cooperation Council countries, while South America, led by Brazil and Argentina's private healthcare sectors, is expected to grow more slowly than Asia-Pacific through 2031.

List of Companies Covered in this Report:

• AngioDynamics
• Argon Medical Devices
• Avanos Medical
• Axiom Medical, Inc.
• B. Braun
• Beckton Dickinson
• Blue Neem Medical Devices Pvt. Ltd.
• Boston Scientific
• Cardinal Health
• Canadian Hospital Specialties Ltd.
• Cook Group
• Galt Medical Corp.
• KM Medical, Inc.
• Medical Components, Inc.
• Medtronic
• Merit Medical Systems
• Mermaid Medical
• Ningbo Honde Medical Instruments Co., Ltd.
• PFM Medical, Inc.
• Polymedicure Ltd.
• REDAX S.p.A.
• Rocket Medical plc
• Teleflex
• UreSil, LLC
• Utah Medical Products

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support